Lysosomal Acid Lipase (LAL) Deficiency Registry

NCT01633489

Status	RECRUITING
Sponsor	Alexion Pharmaceuticals, Inc.
Enrollment	300 participants

Key Eligibility Criteria

Inclusion (2)

- Patients must have a confirmed diagnosis of LAL Deficiency. An Informed Consent and Authorization must be obtained prior to patient enrollment where required under applicable laws and regulations, or a waiver must be obtained by the Institutional Review Board/Independent Ethics Committee.
- Patients cannot be currently participating in an Alexion-sponsored clinical trial. Patients who have concluded participation in an Alexion-sponsored sebelipase alfa clinical trial are eligible to enroll in this Registry, and enrollment in the Registry will not exclude a patient from enrolling in a future clinical trial.

Locations (104 total)

Clinical Trial Site, Phoenix, Arizona, United States
Clinical Trial Site, Stanford, California, United States
Clinical Trial Site, Miramar, Florida, United States
... and 101 more locations